ANMCO/SIMEU Consensus document on the use of reversal agents of antithrombotic therapies in patients with active bleeding or at high-risk of major bleeding events
In recent decades, an incredible evolution in antithrombotic therapies for the treatment of patients suffering from atherosclerosis, atrial fibrillation and venous thromboembolism occurred, leading to the availability of increasingly safe drugs. However, bleeding complications associated with these drugs still have an important health, social and economic impact. Recently, with the aim of improving the acute management of patients with or at risk of major bleeding events, specific reversal agents of antithrombotic drugs have been developed. Although these agents have demonstrated their effectiveness in small pharmacodynamic studies or clinical trials, it is important to consider that the benefit of reversal of an antiplatelet or anticoagulant drug must always be counterbalanced by the possible prothrombotic effect caused by the removal of antithrombotic protection as well as by prothrombotic mechanisms related to bleeding, major surgery or trauma.In this ANMCO/SIMEU consensus document we summarize the main characteristics and efficacy studies of the currently available reversal agents and present practical flow-charts in which we suggest their possible use in patients with active bleeding or at high risk of major bleeding events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 25(2023), 1 vom: 20. Jan., Seite 60-69 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Documento di consenso ANMCO/SIMEU sull’impiego degli agenti di reversione delle terapie antitrombotiche nei pazienti con sanguinamento in atto o ad alto rischio di eventi emorragici |
|---|
| Beteiligte Personen: |
De Luca, Leonardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/4165.41594 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366316656 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366316656 | ||
| 003 | DE-627 | ||
| 005 | 20231227141201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/4165.41594 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM366316656 | ||
| 035 | |a (NLM)38141000 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a De Luca, Leonardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANMCO/SIMEU Consensus document on the use of reversal agents of antithrombotic therapies in patients with active bleeding or at high-risk of major bleeding events |
| 246 | 3 | 3 | |a Documento di consenso ANMCO/SIMEU sull’impiego degli agenti di reversione delle terapie antitrombotiche nei pazienti con sanguinamento in atto o ad alto rischio di eventi emorragici |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In recent decades, an incredible evolution in antithrombotic therapies for the treatment of patients suffering from atherosclerosis, atrial fibrillation and venous thromboembolism occurred, leading to the availability of increasingly safe drugs. However, bleeding complications associated with these drugs still have an important health, social and economic impact. Recently, with the aim of improving the acute management of patients with or at risk of major bleeding events, specific reversal agents of antithrombotic drugs have been developed. Although these agents have demonstrated their effectiveness in small pharmacodynamic studies or clinical trials, it is important to consider that the benefit of reversal of an antiplatelet or anticoagulant drug must always be counterbalanced by the possible prothrombotic effect caused by the removal of antithrombotic protection as well as by prothrombotic mechanisms related to bleeding, major surgery or trauma.In this ANMCO/SIMEU consensus document we summarize the main characteristics and efficacy studies of the currently available reversal agents and present practical flow-charts in which we suggest their possible use in patients with active bleeding or at high risk of major bleeding events | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Pugliese, Francesco Rocco |e verfasserin |4 aut | |
| 700 | 1 | |a Susi, Beniamino |e verfasserin |4 aut | |
| 700 | 1 | |a Navazio, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Corda, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbri, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Scicchitano, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Voza, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vanni, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Bilato, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Geraci, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gabrielli, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Grimaldi, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Colivicchi, Furio |e verfasserin |4 aut | |
| 700 | 1 | |a De Iaco, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 25(2023), 1 vom: 20. Jan., Seite 60-69 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:60-69 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/4165.41594 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 20 |c 01 |h 60-69 | ||